Product Information
DOXAZOSIN MESYLATE 4 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0834 per EA under NDC 59762244007. Its NADAC has been published 186 times since Mar 15, 2023.
FDA first approved this application on Nov 2, 1990. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the doxazosin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
4 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762244007
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXAZOSIN MESYLATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA019668FDA Approved
11/2/1990
TE Code
AB
On Market Since
1/18/2023
Pharmacological Classes
Price Statistics
The NADAC for DOXAZOSIN MESYLATE 4 MG TAB has been published 186 times since Mar 15, 2023, and over the history we have for it it has declined 19.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0834 per EA |
|---|---|
| All-time high | $0.1172 (Jan 10, 2024) |
| All-time low | $0.0834 (Sep 23, 2026) |
| 52-week high | $0.0975 |
| 52-week low | $0.0834 |
| Median price | $0.0941 |
| Average price | $0.0965 |
| Largest weekly change | -16.4% (Jul 17, 2024) |
| Weeks tracked | 186 |
| Tracking since | Mar 15, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doxazosin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doxazosin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXAZOSIN MESYLATE 4 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DOXAZOSIN MESYLATE 4 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $0.0834 per EA (NDC 59762244007), effective Sep 30, 2026.
How has the price of DOXAZOSIN MESYLATE 4 MG TAB changed over time?
Over the history we have for it, the NADAC for DOXAZOSIN MESYLATE 4 MG TAB has declined 19.1%. It has been tracked across 186 weekly CMS publications since Mar 15, 2023.
What are the highest and lowest recorded NADAC prices for DOXAZOSIN MESYLATE 4 MG TAB?
Since Mar 15, 2023, the NADAC for DOXAZOSIN MESYLATE 4 MG TAB has ranged from a low of $0.0834 (Sep 23, 2026) to a high of $0.1172 (Jan 10, 2024), with a median of $0.0941 per EA.
Are there cheaper alternatives to DOXAZOSIN MESYLATE 4 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DOXAZOSIN MESYLATE 4 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXAZOSIN MESYLATE 4 MG TAB?
DOXAZOSIN MESYLATE 4 MG TAB (NDC 59762244007) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.